VIDEO: Minimal IOP changes seen with aflibercept 8 mg or 2 mg at 48 weeks
Click Here to Manage Email Alerts
In this Healio Video Perspective from the ASRS meeting, Jordana G. Fein, MD, MS, of Retina Group of Washington discusses IOP outcomes in patients with diabetic macular edema who were treated with aflibercept 8 mg or aflibercept 2 mg.
The post hoc analysis examined data from the phase 2/3 PHOTON trial and investigated the impact of both doses of aflibercept through 48 weeks.
Overall, “mean changes in pre-dose IOP from baseline did not exceed ±1 mm Hg in the study eye receiving aflibercept 8 mg or 2 mg, suggesting that there was no drift in IOP over time,” Fein said. “The proportion of study and fellow eyes requiring additional IOP-lowering agents were low across all treatment groups, regardless of their glaucoma-related history.”
Collapse
Fein J. Intraocular pressure outcomes with aflibercept 8 mg and 2 mg in patients with diabetic macular edema through week 48 of the phase 2/3 PHOTON trial. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Read more about
Click Here to Manage Email Alerts